HFA
CRSP icon

Hoover Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Hoover Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$49K Buy
300
+200
+200% +$24.3K 0.01% 276
2021
Q1 		$10K Hold
100
– – ﹤0.01% 424
2020
Q4 		$21K Buy
+100
New +$11.8K 0.01% 328

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Hoover Financial Advisors's CRSP Position: Q2 2021 in Review

Hoover Financial Advisors increased its CRISPR Therapeutics (CRSP) stake by 200% in Q2 2021, buying an estimated $24.3K and bringing the position to 300 shares worth $49K. The position accounts for 0.01% of the portfolio, ranked #276.

Hoover Financial Advisors first reported a position in CRSP in Q4 2020 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold CRSP as of Q2 2021.

  • Hoover Financial Advisors held 300 shares of CRISPR Therapeutics worth $49K as of Q2 2021.
  • Hoover Financial Advisors bought 200 CRISPR Therapeutics shares in Q2 2021, an estimated $24.3K.
  • CRISPR Therapeutics made up 0.01% of Hoover Financial Advisors's portfolio in Q2 2021, its #276 holding.
  • Hoover Financial Advisors first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 498 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2021.

Based on Hoover Financial Advisors's 13F filing for Q2 2021, filed 28 Jul 2021.